Skip to main content
AutoRABIT Holding logo

AutoRABIT Holding

Security and trust center evidence

Summary

AutoRABIT Holding has 2 registry-verified rows in the CertReports index, last verified 17 Sep 2026. The strongest row is FedRAMP: FedRAMP Authorized. This page is independent of the vendor’s own trust centre: dates, sources and caveats come from CertReports captures.

Reviewer brief

As of 17 Sep 2026, AutoRABIT Holding is listed in the FedRAMP registry with a status of FedRAMP Authorized, issued 24 Nov 2025, audited by Schellman Compliance, LLC. As of 17 Sep 2026, AutoRABIT Holding is listed in the EU-US Data Privacy Framework registry with active EU-US Certification, SW-US Certification, and UK Extension Certification, issued 7 Oct 2025 and expiring 7 Oct 2026. As of 17 Sep 2026, no public evidence found for a SOC 2 Type II report for AutoRABIT Holding. As of 17 Sep 2026, no public evidence found regarding a BAA offering (HIPAA) for AutoRABIT Holding. As of 17 Sep 2026, no subprocessor information was disclosed in the evidence rows for AutoRABIT Holding.

  • FedRAMP: listed in FedRAMP registry, status 'FedRAMP Authorized', issued 24 Nov 2025, audited by Schellman Compliance, LLC (as of 17 Sep 2026)
  • EU-US Data Privacy Framework: listed in DPF registry, active EU-US/SW-US/UK Extension Certification, issued 7 Oct 2025, expires 7 Oct 2026 (as of 17 Sep 2026)
  • SOC 2 / HIPAA: no public evidence found for either framework as of 17 Sep 2026

Facts only, each dated; nothing here is inferred, scored or advised. Brief generated 17 Sep 2026; it is regenerated whenever a row changes.

Among devops and observability vendors

2verified rows

Category median 1, across 90 indexed devops and observability vendors. AutoRABIT Holding has more verified rows than 88 percent of them.

ci/cdcompliancedevsecopssalesforcesecurity

Compliance grid

Subprocessors

No subprocessor list captured yet.

Similar vendors with evidence

Related by product tags and the DevOps and observability category, ranked by shared tags, description similarity and overlapping evidence. Never by popularity.